Press Releases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 9, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, announced that encouraging clinical findings with the TAP compound, AVE9633, were reported today at the American Society of Hematology (A...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that Mitchel Sayare, PhD., Chairman and CEO of the Company, will participate on the panel, Antibody Leaders and Next Generation Technologies, at the 2007 RBC Capital Markets Healthcare Conference. This 55-minute panel session will begin at 8:00 am E...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 28, 2007--ImmunoGen, Inc. (Nasdaq: IMGN) is scheduled to present at the BMO Capital Markets Healthcare Conference at 11:00 am ET on December 5, 2007. The presentation will be webcast live and can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com. An archive ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that findings with four compounds now in clinical testing will be reported at the American Society of Hematology (ASH) a...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 19, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced the addition of Mr. Richard Wallace to the Company's Board of Directors. Mr. Wallace has more than thirty years of exper...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2007--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 pm ET on Thursday, November 1, 2007 to discuss the Company's financial results for the three-month period ended September 30, 2007 - the first quarter of ImmunoGen's 2008 fiscal year. Management also will provide an update on the...

CAMBRIDGE, Mass., Oct 17, 2007 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that sanofi-aventis has advanced the TAP compound, SAR3419, into Phase I clinical testing. This event triggers a $1 mill...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 3, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that Craig Barrows has joined the Company as Vice President, General Counsel and Secretary. Mr. Barrows has over twenty y...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 9, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three-month period and fiscal year ended June 30, 2007. Mitchel Sayare, Chairman and...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 31, 2007--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceuticals company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that Genentech has started Phase II clinical testing of trastuzumab-DM1. This event triggers a $5 million milestone pay...